Tenax Therapeutics Inc. (TENX)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA Summary
Tenax Therapeutics: A Speculative Buy
Tenax Therapeutics is a speculative BUY, driven by the commercial potential of levosimendan for PH-HFpEF and a favorable risk/reward profile. Levosimendan's Phase III trial remains well powered, but the main end-point risk persists, with a realistic 60–70% chance of success. The risk-adjusted conservative revenue estimate for TENX's lead asset well supports the company's current $450M market cap with substantial upside optionality.
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
Tenax Therapeutics (TENX) initiated with a Buy rating and a $25 price target, implying 127% upside based on DCF analysis. TNX-103, targeting PH-HFpEF, shows a high probability of Phase 3 success with a 65% PoS and strong Phase 2 efficacy signals. Valuation assumes $500M peak sales by 2035, conservative market penetration, and robust cash position minimizing near-term dilution risk.
Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript
Tenax Therapeutics, Inc. ( TENX ) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF November 13, 2025 4:30 PM EST Company Participants Christopher Giordano - CEO, President & Director Stuart Rich - Chief Medical Officer & Director Sanjiv Shah Barry Borlaug Conference Call Participants David Risinger - Leerink Partners LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Presentation Operator Good afternoon, and welcome to the Tenax Therapeutics Virtual KOL Call.
Tenax Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 478,827 | $7.66M | $7.23M | -$426,156.32 | -5.57% |
 Point72 Asset Management LP Point72 Asset Management LP | 533,965 | $6.93M | $8.08M | $1.15M | 16.63% |
| PEB Paul Edward Bottinelli III Boone Capital Management LLC | 200,000 | $3.2M | $3.03M | -$166,000 | -5.19% |
 Kevin Roan Stempoint Capita LLP | 188,700 | $3.02M | $2.85M | -$163,225.5 | -5.41% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 57 | $911 | $862.58 | -$48.42 | -5.32% |
Tenax Therapeutics Inc. (TENX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tenax Therapeutics Inc. ever had a stock split?
Tenax Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Christopher T. Giordano CEO | NASDAQ (CM) Exchange | 88032L605 CUSIP |
| US Country | 16 Employees | - Last Dividend | 3 Jan 2024 Last Split | 2 Jan 1997 IPO Date |
Overview
Tenax Therapeutics, Inc. specializes in the development and commercialization of pharmaceutical products aimed at treating pulmonary arterial hypertension and associated conditions. Originally established as Oxygen Biotherapeutics, Inc., the company underwent a name change to Tenax Therapeutics, Inc. in September 2014 to better reflect its focused mission. With its foundation laid in 1967 and headquartered in Chapel Hill, North Carolina, Tenax Therapeutics has been at the forefront of creating innovative treatments designed to improve the quality of life for patients with complex cardiovascular diseases.
Products and Services
- TNX-101 (IV)
A phase II clinical trial product designed for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction. This innovative treatment aims to alleviate the symptoms and improve the overall health condition of patients suffering from this specific form of heart failure.
- TNX-102
Another advanced therapeutic under Tenax Therapeutics' portfolio, TNX-102 has successfully completed phase II clinical trials. It is also aimed at the treatment of pulmonary hypertension but focuses on patients dealing with heart failure with preserved ejection fraction and associated pulmonary hypertension, providing a broader approach to managing these conditions.
- TNX-103 (levosimendan)
Developed with a specific formulation, TNX-103 (levosimendan) targets pulmonary hypertension associated with heart failure with preserved ejection fraction. By completing phase II clinical trials, this drug aims to offer a new ray of hope for patients by treating the underlying heart conditions that contribute to pulmonary hypertension.
- TNX-201 (imatinib)
A critical addition to the portfolio, TNX-201 incorporates the use of imatinib, a tyrosine kinase inhibitor, offering a treatment solution for chronic myeloid leukemia. This highlights Tenax Therapeutics' versatility in addressing both cardiovascular and oncological health challenges through its product range.
